newsfilter
← Latest News
GlobeNewswire·

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG)